Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
Status:
Terminated
Trial end date:
2016-11-16
Target enrollment:
Participant gender:
Summary
The Neo-PREDICT-HER2 Study is phase II trial to validate predictive markers for the response
evaluation of a combined chemo-immunotherapy in patients with HER2-positive early breast
cancer. The only treatment arm consists of Paclitaxel 80 mg/m2 weekly for 12 weeks with
lapatinib 750 mg P.O. daily and trastuzumab 2 mg/kg IV (loading dose 4 mg/kg) weekly for 12
weeks.